Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
05 sept. 2023 07h00 HE
|
Autolus Therapeutics plc
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
03 août 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
19 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program LONDON,...
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
18 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
06 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years...
Autolus Therapeutics announces publication in Cancer Immunology Research
27 juin 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
20 juin 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
06 juin 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has posted...
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
02 juin 2023 07h00 HE
|
Autolus Therapeutics plc
76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysisPotential best in class...
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL
22 mai 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...